Is Barinthus Biotherapeutics Stock a Good Investment?
Barinthus Biotherapeutics Investment Advice | BRNS |
- Examine Barinthus Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Barinthus Biotherapeutics' leadership team and their track record. Good management can help Barinthus Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Barinthus Biotherapeutics' business and its evolving consumer preferences.
- Compare Barinthus Biotherapeutics' performance and market position to its competitors. Analyze how Barinthus Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Barinthus Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Barinthus Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Barinthus Biotherapeutics plc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Barinthus Biotherapeutics plc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Barinthus Biotherapeutics Stock
Researching Barinthus Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.28. Some equities with similar Price to Book (P/B) outperform the market in the long run. Barinthus Biotherapeutics recorded a loss per share of 1.49. The entity had not issued any dividends in recent years.
To determine if Barinthus Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Barinthus Biotherapeutics' research are outlined below:
| Barinthus Biotherapeutics is way too risky over 90 days horizon | |
| Barinthus Biotherapeutics has some characteristics of a very speculative penny stock | |
| Barinthus Biotherapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 802 K. Net Loss for the year was (73.63 M) with loss before overhead, payroll, taxes, and interest of (30.12 M). | |
| Barinthus Biotherapeutics generates negative cash flow from operations | |
| Barinthus Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hooftman Leon of 140000 shares of Barinthus Biotherapeutics at 1.0 subject to Rule 16b-3 |
Barinthus Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Barinthus Biotherapeutics plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Barinthus Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Barinthus Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Barinthus Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-20 | 2023-12-31 | -0.5 | -0.45 | 0.05 | 10 | ||
2023-08-10 | 2023-06-30 | -0.55 | -0.62 | -0.07 | 12 | ||
2021-08-12 | 2021-06-30 | -0.74 | -0.64 | 0.1 | 13 | ||
2022-03-25 | 2021-12-31 | -0.51 | -0.38 | 0.13 | 25 | ||
2024-05-13 | 2024-03-31 | -0.54 | -0.4 | 0.14 | 25 | ||
2023-03-24 | 2022-12-31 | -0.42 | -0.57 | -0.15 | 35 | ||
2023-11-09 | 2023-09-30 | -0.53 | -0.37 | 0.16 | 30 | ||
2024-11-07 | 2024-09-30 | -0.44 | -0.21 | 0.23 | 52 |
Know Barinthus Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Barinthus Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Barinthus Biotherapeutics plc backward and forwards among themselves. Barinthus Biotherapeutics' institutional investor refers to the entity that pools money to purchase Barinthus Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 12 K | Geode Capital Management, Llc | 2024-09-30 | 11.6 K | Millennium Management Llc | 2024-09-30 | 10.1 K | Blackrock Inc | 2024-09-30 | 6.5 K | Ubs Group Ag | 2024-09-30 | 1.4 K | New England Capital Financial Advisors Llc | 2024-12-31 | 104 | Rhumbline Advisers | 2024-12-31 | 60.0 | Royal Bank Of Canada | 2024-09-30 | 0.0 | M&g Plc | 2024-09-30 | 5.2 M | Alphabet Inc | 2024-12-31 | 1.5 M | Sc China Holding Ltd | 2024-09-30 | 1.4 M |
Barinthus Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.85 M.Market Cap |
|
Barinthus Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | (0.45) | (0.43) |
Determining Barinthus Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Barinthus Biotherapeutics is a good buy. For example, gross profit margin measures Barinthus Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Barinthus Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Barinthus Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Barinthus Biotherapeutics plc. Check Barinthus Biotherapeutics' Beneish M Score to see the likelihood of Barinthus Biotherapeutics' management manipulating its earnings.
Evaluate Barinthus Biotherapeutics' management efficiency
Barinthus Biotherapeutics has return on total asset (ROA) of (0.1865) % which means that it has lost $0.1865 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.326) %, meaning that it created substantial loss on money invested by shareholders. Barinthus Biotherapeutics' management efficiency ratios could be used to measure how well Barinthus Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2025. Return On Capital Employed is likely to drop to -0.39 in 2025. At this time, Barinthus Biotherapeutics' Net Tangible Assets are comparatively stable compared to the past year. Intangible Assets is likely to gain to about 22.6 M in 2025, whereas Total Assets are likely to drop slightly above 183.7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.38 | 4.60 | |
| Tangible Book Value Per Share | 3.51 | 3.68 | |
| Enterprise Value Over EBITDA | (0.20) | (0.21) | |
| Price Book Value Ratio | 0.68 | 0.54 | |
| Enterprise Value Multiple | (0.20) | (0.21) | |
| Price Fair Value | 0.68 | 0.54 | |
| Enterprise Value | 14.4 M | 13.7 M |
Leadership effectiveness at Barinthus Biotherapeutics plc is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta (0.81) |
Basic technical analysis of Barinthus Stock
As of the 17th of February 2025, Barinthus Biotherapeutics shows the Risk Adjusted Performance of 0.0022, mean deviation of 5.17, and Standard Deviation of 6.99. Barinthus Biotherapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Barinthus Biotherapeutics information ratio and skewness to decide if Barinthus Biotherapeutics is priced correctly, providing market reflects its regular price of 1.09 per share. Given that Barinthus Biotherapeutics is a hitting penny stock territory we recommend to closely look at its jensen alpha.Barinthus Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Barinthus Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Barinthus Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Barinthus Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hooftman Leon over a week ago Acquisition by Hooftman Leon of 140000 shares of Barinthus Biotherapeutics at 1.0 subject to Rule 16b-3 | ||
Hooftman Leon over a month ago Acquisition by Hooftman Leon of 195166 shares of Barinthus Biotherapeutics at 2.0 subject to Rule 16b-3 | ||
Geoffrey Lynn over a month ago Insider Trading | ||
Geoffrey Lynn over two months ago Insider Trading | ||
Scheeren Joseph over two months ago Acquisition by Scheeren Joseph of 19516 shares of Barinthus Biotherapeutics at 2.34 subject to Rule 16b-3 | ||
Hooftman Leon over six months ago Insider Trading | ||
Wright Robin over six months ago Acquisition by Wright Robin of 19516 shares of Barinthus Biotherapeutics at 2.34 subject to Rule 16b-3 | ||
Enright William over a year ago Acquisition by Enright William of 455775 shares of Barinthus Biotherapeutics subject to Rule 16b-3 | ||
Enright William over a year ago Acquisition by Enright William of 443981 shares of Barinthus Biotherapeutics subject to Rule 16b-3 |
Barinthus Biotherapeutics' Outstanding Corporate Bonds
Barinthus Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Barinthus Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Barinthus bonds can be classified according to their maturity, which is the date when Barinthus Biotherapeutics plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand Barinthus Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Barinthus Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0022 | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 5.17 | |||
| Coefficient Of Variation | (10,423) | |||
| Standard Deviation | 6.99 | |||
| Variance | 48.87 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.09) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 31.9 | |||
| Value At Risk | (9.65) | |||
| Potential Upside | 10.0 | |||
| Skewness | (1.05) | |||
| Kurtosis | 3.69 |
| Risk Adjusted Performance | 0.0022 | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 5.17 | |||
| Coefficient Of Variation | (10,423) | |||
| Standard Deviation | 6.99 | |||
| Variance | 48.87 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.08) | |||
| Total Risk Alpha | (0.09) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 31.9 | |||
| Value At Risk | (9.65) | |||
| Potential Upside | 10.0 | |||
| Skewness | (1.05) | |||
| Kurtosis | 3.69 |
Consider Barinthus Biotherapeutics' intraday indicators
Barinthus Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Barinthus Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Barinthus Biotherapeutics time-series forecasting models is one of many Barinthus Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Barinthus Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Barinthus Stock media impact
Far too much social signal, news, headlines, and media speculation about Barinthus Biotherapeutics that are available to investors today. That information is available publicly through Barinthus media outlets and privately through word of mouth or via Barinthus internal channels. However, regardless of the origin, that massive amount of Barinthus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Barinthus Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Barinthus Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Barinthus Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Barinthus Biotherapeutics alpha.
Barinthus Biotherapeutics Corporate Management
| Gemma Brown | Chief Officer | Profile | |
| Bernie McDonald | Head IP | Profile | |
| Geoffrey Lynn | Senior Immunotherapies | Profile | |
| Chris Ellis | Chief Officer | Profile | |
| Graham Griffiths | Chief Officer | Profile | |
| Elizabeth MBA | Head Operations | Profile |
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.